Gender differences vary across geographical settings and are poorly reported in the literature. The aim of this study was to evaluate demographics and clinical characteristics of participants from the Australian HIV Observational Database (AHOD), and to explore any differences between females and males in the rate of new clinical outcomes, as well as initial immunological and virological response to antiretroviral therapy.
Time to a new clinical end-point, all-cause mortality and/or AIDS illness was analysed using standard survival methods. Univariate and covariate adjusted Cox proportional hazard models were used to evaluate the time to plasma viral load suppression in all patients that initiated antiretroviral therapy (ART) and time to switching from a first-line ART to a second-line ART regimen.
There was no significant difference between females and males for the hazard of all-cause mortality [adjusted hazard ratio: 0.98 (0.51, 1.55), P = 0.67], new AIDS illness [adjusted hazard ratio: 0.75 (0.38, 1.48), P = 0.41] or a composite end-point [adjusted hazard ratio: 0.74 (0.45, 1.21), P = 0.23]. Incident rates of all-cause mortality were similar between females and males; 1.14 (0.61, 1.95) vs 1.28 (1.12, 1.45) per 100 person years. Virological response to ART was similar for females and males when measured as time to viral suppression and/or time to virological failure.
This study supports current Australian HIV clinical care as providing equivalent standards of care for male and female HIV-positive patients. Future studies should compare ART-associated toxicity differences between ART-associated toxicity differences between men and women living with HIV in Australia.
Purchase full article at: http://goo.gl/uo3P3Z
By: Michelle L. Giles A B I, Marin C. Zapata C, Stephen T. Wright D E, Kathy PetoumenosD, Miriam Grotowski F, Jennifer Broom G, Matthew G. Law D and Catherine C. O’Connor C D H
A Department of Infectious Diseases, Monash University, Clayton, Vic. 3168, Australia. B Monash Infectious Diseases, Monash Health, Clayton, Vic. 3168, Australia. C RPA Sexual Health, Sydney Local Health District, Sydney, NSW 2050, Australia. D The Kirby Institute, UNSW Australia, Sydney, NSW 2052, Australia. E School of Mathematical and Physical Sciences, University of Technology, Sydney, NSW 2007, Australia. F Tamworth Sexual Health Service, Tamworth, NSW 2340, Australia. G Department of Medicine, Nambour Hospital, Nambour, Qld 4560, Australia. H Central Clinical School, University of Sydney, Sydney, NSW 2052, Australia. I Corresponding author. Email: email@example.com
Sex Health. 2016 Feb 1. doi: 10.1071/SH15124.
More at: https://twitter.com/hiv insight